用ROS激活基原药用于癌细胞中的化学选择性共价向向
Shijin Zhang1, Qinchuan Wei1, Jiarong Lv1
1National Engineering Research Center of Ophthalmology and Optometry, School of Biomedical Engineering, Eye Hospital, Wenzhou Medical University, Wenzhou 325027, China.
Journal of medicinal chemistry
|February 26, 2026
概括
我们开发了IRS1,一种向的共价药物,可以自组装成纳米粒子. 它选择性地准癌细胞,释放药物有效载荷以诱导癌细胞死亡,降低毒性.
科学领域:
- 药物运输 药物运输 药物运输
- 纳米医学是一种纳米医学.
- 癌症治疗方法 癌症治疗方法
背景情况:
- 联药物具有很高的选择性,但面临的挑战是异于目标的反应性.
- 开发有针对性的疗法对于尽量减少癌症治疗中的全身毒性至关重要.
研究的目的:
- 设计和评估IRS1,一种针对向癌症抑制的新型基前药物.
- 研究IRS1.1的自我组装,瘤向和药物释放机制.
主要方法:
- IRS1合成包括一个RGD动机,ROS响应单元和ambucil弹头.
- 描述IRS1自组装成纳米颗粒和转化为纳米纤维的特征.
- 癌细胞死亡诱导的体外评估和体内评估在阴膜黑色素瘤异种移植模型中.
主要成果:
- 通过整合素介导,IRS1自组装成纳米颗粒,通过整合素介导准皮膜黑色素瘤细胞.
- 由ROS触发的IRS1纳米粒子转化为纳米纤维暴露了共价弹头.
- 通过破坏膜完整性和激活细胞灭亡,IRS1诱导癌细胞死亡,在体内表现出强大的抗瘤疗效,毒性降低.
结论:
- 在瘤选择性共价疗法中,IRS1代表了一种有前途的类重构策略.
- 开发的前药物通过向药物输送和受控释放,证明了有效的癌症抑制.
相关概念视频
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
01:24Modified-Release Drug Delivery Systems: Site-Targeted
51
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
51